The Technical Analyst
CVRx, Inc. [CVRX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
CVRx, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.07% $14.39
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 310.76 mill |
| EPS: | -1.990 |
| P/E: | -7.23 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 21.60 mill |
| Avg Daily Volume: | 0.138 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.23 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -7.23 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 13.36 - 15.42 ( +/- 7.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Palmer Craig E. | Buy | 151 | Common Stock |
| 2024-03-25 | Palmer Craig E. | Buy | 404 | Common Stock |
| 2024-03-25 | Palmer Craig E. | Buy | 379 | Common Stock |
| 2024-03-25 | Palmer Craig E. | Sell | 151 | Stock Option (right to buy) |
| 2024-02-29 | Johnson & Johnson | Buy | 79 | Common Stock |
| INSIDER POWER |
|---|
| -42.21 |
| Last 98 transactions |
| Buy: 1 792 667 | Sell: 4 181 141 |
Forecast:
16:00 - $14.39
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $14.39
Forecast 2: 16:00 - $14.39
Forecast 3: 16:00 - $14.39
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.39 (-0.07% ) |
| Volume | 0.138 mill |
| Avg. Vol. | 0.138 mill |
| % of Avg. Vol | 99.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CVRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $24.50 | N/A | Active |
|---|
CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Last 10 Buy Signals
Latest Press Releases
2024-04-16 16:30:00 - Press Release
Cvrx To Report First Quarter 2024 Financial And Operating Results And Host Conference Call On April 30th, 2024
Minneapolis, april 16, 2024 (globe newswire) -- cvrx, inc. (nasdaq: cvrx) (“cvrx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on tuesday, april 30th, 2024. the company will host a conference call to review its results at 5:00pm eastern time the same day.
2024-04-15 07:30:00 - Press Release
Cvrx Announces Availability Of Additional Data Supporting Long-term Benefits Of Barostim
Beat-hf trial data published in the european journal of heart failure and new abstracts presented at tht conference
2024-01-31 08:00:00 - Press Release
Cvrx Announces Appointment Of Kevin Hykes As President And Chief Executive Officer
Minneapolis, jan. 31, 2024 (globe newswire) -- cvrx, inc . (nasdaq: cvrx) (“cvrx”), a commercial-stage medical device company, announced today the appointment of kevin hykes as the company's new president and chief executive officer, effective february 12. hykes will continue to serve on the company's board of directors. yared will retire from the company and resign his board seat concurrent with hykes' appointment and has agreed to consult with the company to ensure a seamless transition.
2024-01-25 16:05:00 - Press Release
Cvrx Reports Fourth Quarter And Full Year 2023 Financial And Operating Results
Minneapolis, jan. 25, 2024 (globe newswire) -- cvrx, inc. (“cvrx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook.
2024-01-11 16:30:00 - Press Release
Cvrx To Report Fourth Quarter 2023 Financial And Operating Results And Host Conference Call On January 25th, 2024
Minneapolis, jan. 11, 2024 (globe newswire) -- cvrx, inc. (nasdaq: cvrx) (“cvrx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on thursday, january 25th, 2024. the company will host a conference call to review its results at 4:30pm eastern time the same day.
Latest News
2024-04-19 12:16:03 - Zacks Investment Research
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
2024-04-16 16:30:00 - GlobeNewsWire
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm Eastern Time the same day.
2024-01-30 07:21:20 - Zacks Investment Research
New Strong Buy Stocks for January 30th
HCC, EGO, WRLD, PBPB and CVRX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.
2024-01-25 22:37:10 - Seeking Alpha
CVRx, Inc. (CVRX) Q4 2023 Earnings Call Transcript
2024-01-25 18:46:05 - Zacks Investment Research
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.51 per share a year ago.
2024-01-22 13:00:52 - Zacks Investment Research
CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-01-11 16:30:00 - GlobeNewsWire
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
2024-01-11 10:34:27 - Zacks Investment Research
What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'
CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2023-12-27 16:30:00 - GlobeNewsWire
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. The Company is scheduled to present at 3:45pm Pacific Time the same day via webcast.
2023-12-27 09:01:26 - Zacks Investment Research
CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.